Stockscreener 앱 받기
29.34
5.35%
1.49
시장 영업 전:
28.85
-0.49
-1.67%
전일 마감가:
$27.85
열려 있는:
$27.98
하루 거래량:
346.65K
Relative Volume:
0.99
시가총액:
$1.40B
수익:
-
순이익/손실:
$-97.70M
주가수익비율:
-10.90
EPS:
-2.6925
순현금흐름:
$-77.89M
1주 성능:
-2.85%
1개월 성능:
+10.99%
6개월 성능:
+91.14%
1년 성능:
+193.69%
1일 변동 폭
$27.59
$29.50
1주일 범위
$26.48
$30.34
52주 변동 폭
$7.40
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
명칭
Rapport Therapeutics Inc
전화
857-321-8020
주소
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
29.34 | 1.33B | 0 | -97.70M | -77.89M | -2.6925 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Wells Fargo | Overweight |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-16 | 개시 | Truist | Buy |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-04-08 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 개시 | Jefferies | Buy |
| 2024-07-02 | 개시 | Stifel | Buy |
| 2024-07-02 | 개시 | TD Cowen | Buy |
모두보기
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday - MarketBeat
RAPP Should I Buy - Intellectia AI
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
RAPP PE Ratio & Valuation, Is RAPP Overvalued - Intellectia AI
Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling a 73.63% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Buyout Rumor: What is the cash position of Rapport Therapeutics Inc2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Highs Report: What hedge funds are buying Rapport Therapeutics IncGap Down & Consistent Return Investment Signals - baoquankhu1.vn
RAPP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Investor Outlook: Analyzing A 70.80% Potential Upside - DirectorsTalk Interviews
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock - MarketBeat
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells 5,833 Shares of Stock - MarketBeat
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RAPP Stock Price and Chart — NASDAQ:RAPP - TradingView
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate - Yahoo Finance
Can Rapport Therapeutics Inc. stock deliver surprise earnings beatMarket Sentiment Review & Weekly High Momentum Picks - mfd.ru
RAPP Technical Analysis & Stock Price Forecast - Intellectia AI
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Deep Dive Into Its 83% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Does Rapport Therapeutics Inc. have strong fundamentals2025 Price Action Summary & Technical Pattern Based Signals - mfd.ru
Will Rapport Therapeutics Inc. stock split again soonInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Understanding Momentum Shifts in (RAPP) - Stock Traders Daily
RSI Check: What hedge funds are buying Rapport Therapeutics IncM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
A Look At Rapport Therapeutics (RAPP) Valuation After Fresh Overweight Rating From Wells Fargo - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Investor Outlook: A 100% Upside Potential In Biotech Sector - DirectorsTalk Interviews
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Wells Fargo & Company - Defense World
Wells Fargo Initiates Coverage of Rapport Therapeutics (RAPP) with Overweight Recommendation - Nasdaq
Rapport Therapeutics (RAPP): Analyst Initiates Coverage with Ove - GuruFocus
Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target - marketscreener.com
Wells Fargo & Company Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Aug Final Week: What are Rapport Therapeutics Inc.’s technical support levels2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Whale Trades: What is the dividend yield of PMGC Holdings IncWeekly Trading Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Breakouts: Why is Rapport Therapeutics Inc stock going upStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
Activity Recap: What hedge funds are buying Rapport Therapeutics IncJuly 2025 PreEarnings & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Promising Biotech with Nearly 95% Upside Potential - DirectorsTalk Interviews
Will Rapport Therapeutics Inc. stock gain from strong economyMarket Trend Review & Verified Stock Trade Ideas - mfd.ru
Should I buy Rapport Therapeutics Inc. stock nowCEO Change & Intraday High Probability Setup Alerts - mfd.ru
Is Rapport Therapeutics Inc. undervalued by DCF analysis2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
Layoff Watch: Is Rapport Therapeutics Inc gaining market shareQuarterly Portfolio Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (RAPP) Movement - Stock Traders Daily
Retail Surge: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen - MarketBeat
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Australia
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Rapport Therapeutics Inc (RAPP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rapport Therapeutics Inc 주식 (RAPP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Feb 18 '26 |
Sale |
29.36 |
5,083 |
149,212 |
20,729 |
| Bredt David | Chief Scientific Officer |
Feb 19 '26 |
Option Exercise |
1.80 |
6,000 |
10,800 |
393,075 |
| Bredt David | Chief Scientific Officer |
Feb 17 '26 |
Sale |
29.02 |
8,500 |
246,655 |
387,075 |
| Ceesay Abraham | Chief Executive Officer |
Jan 20 '26 |
Sale |
26.12 |
5,833 |
152,333 |
562,080 |
| Ceesay Abraham | Chief Executive Officer |
Jan 20 '26 |
Sale |
26.11 |
5,083 |
132,737 |
25,812 |
| Bredt David | Chief Scientific Officer |
Jan 15 '26 |
Sale |
26.84 |
8,500 |
228,132 |
395,575 |
0.11%
6.00%
자본화:
|
볼륨(24시간):